Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 359-363

  Kinoshita, Y ^a   Kuratsukuri, K ^a   Newman, N ^a   Rovito Jr , P M ^a   Kaumaya, P T P ^b   Wang, C Y ^a,c   Haas, G P ^a,c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibody; Antitumor activity; Glutamate carboxypeptidase II; LNCaP; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 24.4E6; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; EPITOPES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 30544439961     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500835     Document Type: Article

References (28)

1. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539.
2. Barrett AJ. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme Nomenclature. Recommendations 1992. Supplement 4: Corrections and additions (1997). Eur J Biochem 1997; 250: 1-6.
3. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93: 749-753.
4. Luthi-Carter R et al. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998; 286: 1020-1025.
5. Israeli RS et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230.
6. Su SL et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995; 55: 1441-1443.
7. Schmittgen TD et al. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 323-329.
8. Liu H et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629-3634.
9. Chang SS et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198.
10. Kuratsukuri K et al. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Intl J Cancer 2002; 102: 244-249.
11. Davis MI et al. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Pro Natl Acad Sci USA 2005; 102: 5981-5986.
12. Dakappagari NK et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60: 3782-3789.
13. Kaumaya PTP et al. 'De novo' engineering of peptide immunogenic and antigenic determinants as potential vaccines. In: Basava C, Anantharamaiah GM (eds). Peptides: Design, Synthesis and Biological Activity. Birkhauser: Boston, 1994, pp 133-164.
14. Land SJ et al. Purification and characterization of a rat hepatic acetyltransferase that can metabolize aromatic amine derivatives. Carcinogenesis 1993; 14: 1441-1449.
15. Bumke MA, Neri D. Affinity measurements by band shift and competition ELISA. In: Kontermann R, Dubel S (eds). Antibody Engineering. Springer-Verlag: New York, 2001, pp 385-396.
16. Soos G et al. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res 1997; 17: 4253-4258.
17. Slusher BS et al. Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 1990; 265: 21297-21301.
18. Bacich DJ et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001; 12: 117-123.
19. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-936.
20. Sokoloff RL et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150-157.
21. Grauer LS et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998; 58: 4787-4789.
22. Crawford ED et al. Hormone refractory prostate cancer. Urol 1999; 54: S1-S7.
23. Sanda MG et al. Molecular characterization of defective antigen presentation in human prostate cancer. J Natl Cancer Inst 1995; 87: 280-285.
24. Blades RA et al. Loss of class I expression in prostate cancer: implications for immunotherapy. Urol 1995; 46: 681-687.
25. Bander N et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233-239.
26. Bander NH et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars Oncol 2003; 30: 667-676.
27. Bander NH et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721.
28. Henry MD et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64: 7995-8001.